

Biff F Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899842/publications.pdf>

Version: 2024-02-01

135
papers

6,794
citations

61984

43
h-index

66911

78
g-index

135
all docs

135
docs citations

135
times ranked

7560
citing authors

#	ARTICLE	IF	CITATIONS
1	The sexual dimorphism of obesity. <i>Molecular and Cellular Endocrinology</i> , 2015, 402, 113-119.	3.2	609
2	Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System. <i>New England Journal of Medicine</i> , 2004, 351, 585-592.	27.0	519
3	Regulation of Potassium Homeostasis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1050-1060.	4.5	351
4	Renal Dysfunction Complicating the Treatment of Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 1256-1261.	27.0	286
5	Hyponatremia in patients with central nervous system disease: SIADH versus CSW. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 182-187.	7.1	260
6	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	5.2	260
7	Hypothalamic PGC-1 β Protects Against High-Fat Diet Exposure by Regulating ER α . <i>Cell Reports</i> , 2014, 9, 633-645.	6.4	159
8	Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2015, 373, 548-559.	27.0	154
9	Physiology and pathophysiology of potassium homeostasis. <i>American Journal of Physiology - Advances in Physiology Education</i> , 2016, 40, 480-490.	1.6	153
10	Recent Advances in the Prevention and Management of Intradialytic Hypotension. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 8-11.	6.1	151
11	Determinants of body fat distribution in humans may provide insight about obesity-related health risks. <i>Journal of Lipid Research</i> , 2019, 60, 1710-1719.	4.2	132
12	Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 262-268.	0.7	125
13	Causes and Management of Hyponatremia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1694-1702.	1.9	125
14	Approach to Fluid and Electrolyte Disorders and Acid-Base Problems. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, 195-213.	1.6	125
15	The effects of oestrogens and their receptors on cardiometabolic health. <i>Nature Reviews Endocrinology</i> , 2017, 13, 352-364.	9.6	122
16	Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019. <i>American Journal of Kidney Diseases</i> , 2019, 74, 682-695.	1.9	120
17	Sexual Dysfunction in Men and Women With Chronic Kidney Disease and End-Stage Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 48-60.	2.1	118
18	Thiazide-Associated Hyponatremia: A Major Dilemma Affecting Treatment. <i>American Journal of Nephrology</i> , 2017, 45, 417-419.	3.1	100

#	ARTICLE	IF	CITATIONS
19	Oxygen sensing and metabolic homeostasis. <i>Molecular and Cellular Endocrinology</i> , 2014, 397, 51-58.	3.2	89
20	Clinical Management of Hyperkalemia. <i>Mayo Clinic Proceedings</i> , 2021, 96, 744-762.	3.0	87
21	Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. <i>Drugs</i> , 2007, 67, 1309-1327.	10.9	86
22	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 783-800.	2.3	81
23	Achieving the Benefits of a High-Potassium, Paleolithic Diet, Without the Toxicity. <i>Mayo Clinic Proceedings</i> , 2016, 91, 496-508.	3.0	79
24	Metabolic alkalosis.. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 1462-1469.	6.1	78
25	Intravenous immunoglobulin-induced osmotic nephrosis. <i>Archives of Internal Medicine</i> , 1994, 154, 1985-1987.	3.8	72
26	Electrolyte Disturbances in Patients with Chronic Alcohol-Use Disorder. <i>New England Journal of Medicine</i> , 2017, 377, 1368-1377.	27.0	71
27	Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2007, 27, 287-293.	3.1	69
28	Diagnosis and treatment of hyperkalemia. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 934-942.	1.3	68
29	Gonadal dysfunction in chronic kidney disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 117-130.	5.7	65
30	Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 339-354.	3.0	64
31	Metabolic Complications Associated With Use of Diuretics. <i>Seminars in Nephrology</i> , 2011, 31, 542-552.	1.6	62
32	Activation of natriuretic peptides and the sympathetic nervous system following Roux-en-Y gastric bypass is associated with gonadal adipose tissues browning. <i>Molecular Metabolism</i> , 2015, 4, 427-436.	6.5	60
33	Ascent to altitude as a weight loss method: The good and bad of hypoxia inducible factor activation. <i>Obesity</i> , 2014, 22, 311-317.	3.0	59
34	A sexually dimorphic hypothalamic response to chronic high-fat diet consumption. <i>International Journal of Obesity</i> , 2016, 40, 206-209.	3.4	59
35	Liddle's Syndrome. <i>American Journal of Medicine</i> , 1998, 104, 301-309.	1.5	57
36	Non-shivering thermogenesis as a mechanism to facilitate sustainable weight loss. <i>Obesity Reviews</i> , 2017, 18, 819-831.	6.5	54

#	ARTICLE	IF	CITATIONS
37	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>American Journal of Kidney Diseases</i> , 2017, 70, 844-858.	1.9	53
38	A Physiologic-Based Approach to the Evaluation of a Patient With Hyperkalemia. <i>American Journal of Kidney Diseases</i> , 2010, 56, 387-393.	1.9	52
39	A Physiologic-Based Approach to the Evaluation of a Patient With Hypokalemia. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1184-1190.	1.9	52
40	Impaired Renal Autoregulation: Implications for the Genesis of Hypertension and Hypertension-Induced Renal Injury. <i>American Journal of the Medical Sciences</i> , 2001, 321, 388-400.	1.1	51
41	Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 11-23.	1.4	50
42	Activation of estrogen receptor alpha induces beiging of adipocytes. <i>Molecular Metabolism</i> , 2018, 18, 51-59.	6.5	49
43	Physiology and Pathophysiology With Ascent to Altitude. <i>American Journal of the Medical Sciences</i> , 2010, 340, 69-77.	1.1	46
44	Maternal high-fat diet is associated with impaired fetal lung development. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L360-L368.	2.9	44
45	Disturbances in Renal Autoregulation and the Susceptibility to Hypertension-Induced Chronic Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2004, 328, 330-343.	1.1	43
46	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1973-1975.	0.7	42
47	Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1284-1291.	4.5	42
48	ER α upregulates Phd3 to ameliorate HIF-1 induced fibrosis and inflammation in adipose tissue. <i>Molecular Metabolism</i> , 2014, 3, 642-651.	6.5	39
49	The role of estrogens in the adipose tissue milieu. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 127-143.	3.8	39
50	Salicylate Toxicity. <i>New England Journal of Medicine</i> , 2020, 382, 2544-2555.	27.0	38
51	Hyperkalemia across the Continuum of Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 155-157.	4.5	36
52	Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. <i>Seminars in Nephrology</i> , 1995, 15, 214-27.	1.6	36
53	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2016, 129, 858-865.	1.5	35
54	Sex and Gender: Critical Variables in Pre-Clinical and Clinical Medical Research. <i>Cell Metabolism</i> , 2016, 24, 203-209.	16.2	34

#	ARTICLE	IF	CITATIONS
55	The Use of Selected Urine Chemistries in the Diagnosis of Kidney Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 306-316.	4.5	34
56	Renal complications associated with use of nonsteroidal anti-inflammatory agents. <i>Journal of Investigative Medicine</i> , 1995, 43, 516-33.	1.6	34
57	Individualizing the Dialysate in the Hemodialysis Patient. <i>Seminars in Dialysis</i> , 2001, 14, 41-49.	1.3	33
58	Do estrogens enhance activation of brown and beigeing of adipose tissues?. <i>Physiology and Behavior</i> , 2018, 187, 24-31.	2.1	31
59	Starvation Ketosis and the Kidney. <i>American Journal of Nephrology</i> , 2021, 52, 467-478.	3.1	31
60	Renal Tubular Acidosis and Management Strategies: A Narrative Review. <i>Advances in Therapy</i> , 2021, 38, 949-968.	2.9	31
61	Evaluation and Treatment of Respiratory Alkalosis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 834-838.	1.9	30
62	Impact of estrogens and estrogen receptor-1± in brain lipid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E7-E14.	3.5	30
63	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1162-1166.	2.3	28
64	Outcomes associated with hypogonadism in men with chronic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 342-347.	1.4	25
65	Hyponatremia in the Intensive Care Unit. <i>Seminars in Nephrology</i> , 2009, 29, 257-270.	1.6	25
66	Let Them Eat Healthy: Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease?. , 2020, 30, 475-483.		23
67	Rhabdomyolysis and Acute Renal Failure Associated with Influenza Virus Type B Infection. <i>American Journal of the Medical Sciences</i> , 2006, 332, 88-89.	1.1	22
68	Sex and media: Considerations for cell culture studies. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2018, 35, 435-440.	1.5	21
69	Management of Hypertension in Patients with Chronic Kidney Disease and Diabetes Mellitus. <i>American Journal of Medicine</i> , 2008, 121, S16-S22.	1.5	20
70	Improving BP Control with Combined Renin-Angiotensin System Blockade and Thiazide Diuretics in Hypertensive Patients with Diabetes Mellitus or Kidney Disease. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 9-14.	2.2	20
71	Metabolic complications associated with use of thiazide diuretics. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 381-392.	2.3	19
72	New options for the management of chronic hyperkalemia. <i>Kidney International Supplements</i> , 2017, 7, 164-170.	14.2	19

#	ARTICLE	IF	CITATIONS
73	Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney Disease. American Journal of Nephrology, 2008, 28, 381-390.	3.1	18
74	An Emerging Role of Natriuretic Peptides. Mayo Clinic Proceedings, 2015, 90, 1666-1678.	3.0	16
75	Potassium Homeostasis, Chronic Kidney Disease, and the Plant-Enriched Diets. Kidney360, 2020, 1, 65-71.	2.1	16
76	The renal tubule in the progression of chronic renal failure. Journal of Investigative Medicine, 1997, 45, 346-61.	1.6	16
77	Hyperkalemia. JAMA - Journal of the American Medical Association, 2015, 314, 2405.	7.4	15
78	Vasopressin Receptor Antagonists. Current Hypertension Reports, 2015, 17, 510.	3.5	15
79	The Effect of Dialysate Composition on Systemic Hemodynamics. Seminars in Dialysis, 1992, 5, 54-60.	1.3	14
80	Optimizing Blood Pressure Control in Patients with Chronic Kidney Disease. Baylor University Medical Center Proceedings, 2010, 23, 239-245.	0.5	13
81	Pathogenesis of ascites and renal salt retention in cirrhosis. Journal of Investigative Medicine, 1999, 47, 183-202.	1.6	13
82	Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clinic Proceedings, 2022, 97, 761-776.	3.0	13
83	The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia. Electrolyte and Blood Pressure, 2013, 11, 1.	1.8	12
84	Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet?. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 467-472.	4.5	12
85	Extrarenal Effects of Aldosterone on Potassium Homeostasis. Kidney360, 2022, 3, 561-568.	2.1	12
86	Hyperkalemia in Predialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1201-1202.	4.5	11
87	Metabolic Acidosis. , 2010, , 155-166.		10
88	Treatment of Abnormalities of Potassium Homeostasis in CKD. Advances in Chronic Kidney Disease, 2017, 24, 319-324.	1.4	10
89	Blood pressure lowering and potassium intake. Journal of Human Hypertension, 2020, 34, 671-672.	2.2	10
90	Hypertension management in patients with chronic kidney disease. Current Hypertension Reports, 2008, 10, 367-373.	3.5	9

#	ARTICLE	IF	CITATIONS
91	Renal Considerations in the Treatment of Hypertension. American Journal of Hypertension, 2018, 31, 394-401.	2.0	9
92	Fluid overload as a therapeutic target for the preservative management of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 22-28.	2.0	9
93	Treating dyslipidemia to slow the progression of chronic renal failure. American Journal of Medicine, 2003, 114, 411-412.	1.5	8
94	<i>Opinion</i> : Can Chronic Volume Overload Be Recognized and Prevented in Hemodialysis Patients?. Seminars in Dialysis, 2009, 22, 489-491.	1.3	8
95	Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia. Mayo Clinic Proceedings, 2017, 92, 1248-1260.	3.0	8
96	Diagnostic approach and management of inpatient hyponatremia. Journal of Hospital Medicine, 2010, 5, S1-7.	1.4	7
97	Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. Journal of Human Hypertension, 2010, 24, 483-491.	2.2	7
98	Altered Prostaglandin Signaling as a Cause of Thiazide-Induced Hyponatremia. American Journal of Kidney Diseases, 2018, 71, 769-771.	1.9	7
99	Pathogenesis of edema formation in the nephrotic syndrome. Kidney International, Supplement, 1997, 59, S21-7.	0.1	7
100	Physiology and Pathophysiology of Sodium Retention and Wastage. , 2008, , 1005-1049.		6
101	Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Current Medical Research and Opinion, 2009, 25, 2933-2949.	1.9	6
102	Nephrology Quiz and Questionnaire. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1141-1160.	4.5	6
103	Sex matters: COVID-19 in kidney transplantation. Kidney International, 2021, 99, 555-558.	5.2	6
104	Documentation of fungal pyelonephritis of the renal allograft by fine needle aspiration cytology. Transplantation Proceedings, 1989, 21, 3598-9.	0.6	6
105	Outcomes associated with hypogonadism in men with chronic kidney disease. Advances in Chronic Kidney Disease, 2004, 11, 342-7.	1.4	6
106	Electrolyte Disturbances in Chronic Alcohol-Use Disorder. New England Journal of Medicine, 2018, 378, 202-204.	27.0	5
107	Potassium binding for conservative and preservative management of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 29-38.	2.0	5
108	Gastrointestinal potassium binding in hemodialysis. Kidney International, 2020, 98, 1095-1097.	5.2	5

#	ARTICLE	IF	CITATIONS
109	Hyperchloremic normal gap metabolic acidosis. <i>Minerva Endocrinologica</i> , 2020, 44, 363-377.	1.8	5
110	Normal Acid-Base Balance. , 2010, , 149-154.		4
111	Why are some dialysis patients chronically hypotensive in the absence of heart disease and volume depletion?. <i>Seminars in Dialysis</i> , 2011, 24, 404-405.	1.3	4
112	American Society of Nephrology Quiz and Questionnaire 2013. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1132-1137.	4.5	4
113	Cardiovascular Benefits of a Diet Enriched in Fruits and Vegetables. <i>American Journal of Nephrology</i> , 2019, 49, 435-437.	3.1	4
114	Strategies to Counter Weight Loss-Induced Reductions in Metabolic Rate. <i>Current Sports Medicine Reports</i> , 2019, 18, 258-265.	1.2	4
115	Hyponatremia in the Cancer Patient. <i>Journal of Onco-Nephrology</i> , 2017, 1, 87-94.	0.6	3
116	A Universally Accepted Definition of Gender Will Positively Impact Societal Understanding, Acceptance, and Appropriateness of Health Care. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2235-2243.	3.0	3
117	Cerebral Salt Wasting Is a Real Cause of Hyponatremia: COMMENTARY. <i>Kidney360</i> , 2023, 4, e445-e447.	2.1	3
118	Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient. <i>Heart Failure Clinics</i> , 2008, 4, 439-448.	2.1	2
119	New horizons in the pharmacologic approach to hyponatremia: The V2 receptor antagonists. <i>Journal of Hospital Medicine</i> , 2010, 5, S27-S32.	1.4	2
120	Pathophysiology of Sodium Retention and Wastage. , 2013, , 1283-1317.		2
121	Sex, Gender, and Transgender: Metabolic Impact of Cross Hormone Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 611-627.	1.6	2
122	Dialysate Composition. , 2017, , 152-161.e1.		2
123	Metabolic disturbances in chronic renal failure. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2002, 13, 273-80.	0.3	2
124	Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors. <i>American Journal of Kidney Diseases</i> , 2022, 80, 158-160.	1.9	2
125	American Society of Nephrology Quiz and Questionnaire 2012: Electrolytes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1048-1053.	4.5	1
126	Potassium Metabolism in Chronic Kidney Disease. , 2015, , 381-390.		1

#	ARTICLE	IF	CITATIONS
127	Amenorrhea and Estrogen Disorders in Kidney Disease. <i>Seminars in Nephrology</i> , 2021, 41, 126-132.	1.6	1
128	Systemic complications of nonsteroidal anti-inflammatory drug use. <i>Advances in Internal Medicine</i> , 1996, 41, 605-39.	0.9	1
129	Metabolic Abnormalities: Evaluation of Sexual Dysfunction. , 2008, , 930-939.		0
130	Management of sexual dysfunction in uremic patients. <i>Dialysis and Transplantation</i> , 2010, 39, 370-372.	0.2	0
131	Screening Tests for Renal Impairment in Patients with Type 2 Diabetes: The what, when, and how. <i>Postgraduate Medicine</i> , 2011, 123, 7-14.	2.0	0
132	Nephrology Quiz and Questionnaire: Electrolytes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1047-1052.	4.5	0
133	Potassium Metabolism in Chronic Kidney Disease. , 2020, , 643-659.		0
134	The authors reply. <i>Kidney International</i> , 2020, 98, 785.	5.2	0
135	Respiratory acidâ€base disorders. , 2012, , 605-611.		0